These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 31693290)

  • 1. The good and bad of therapeutic strategies that directly target α-synuclein.
    Longhena F; Faustini G; Brembati V; Pizzi M; Bellucci A
    IUBMB Life; 2020 Apr; 72(4):590-600. PubMed ID: 31693290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy.
    Nimmo JT; Verma A; Dodart JC; Wang CY; Savistchenko J; Melki R; Carare RO; Nicoll JAR
    Alzheimers Res Ther; 2020 Nov; 12(1):159. PubMed ID: 33256825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapies: The next logical Step for the treatment of synucleinopathies?
    Valera E; Masliah E
    Mov Disord; 2016 Feb; 31(2):225-34. PubMed ID: 26388203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. α-Synuclein strains cause distinct synucleinopathies after local and systemic administration.
    Peelaerts W; Bousset L; Van der Perren A; Moskalyuk A; Pulizzi R; Giugliano M; Van den Haute C; Melki R; Baekelandt V
    Nature; 2015 Jun; 522(7556):340-4. PubMed ID: 26061766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A simple, versatile and robust centrifugation-based filtration protocol for the isolation and quantification of α-synuclein monomers, oligomers and fibrils: Towards improving experimental reproducibility in α-synuclein research.
    Kumar ST; Donzelli S; Chiki A; Syed MMK; Lashuel HA
    J Neurochem; 2020 Apr; 153(1):103-119. PubMed ID: 31925956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple system atrophy-associated oligodendroglial protein p25α stimulates formation of novel α-synuclein strain with enhanced neurodegenerative potential.
    Ferreira N; Gram H; Sorrentino ZA; Gregersen E; Schmidt SI; Reimer L; Betzer C; Perez-Gozalbo C; Beltoja M; Nagaraj M; Wang J; Nowak JS; Dong M; Willén K; Cholak E; Bjerregaard-Andersen K; Mendez N; Rabadia P; Shahnawaz M; Soto C; Otzen DE; Akbey Ü; Meyer M; Giasson BI; Romero-Ramos M; Jensen PH
    Acta Neuropathol; 2021 Jul; 142(1):87-115. PubMed ID: 33978813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic approaches to target alpha-synuclein pathology.
    Brundin P; Dave KD; Kordower JH
    Exp Neurol; 2017 Dec; 298(Pt B):225-235. PubMed ID: 28987463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upregulation of α-synuclein following immune activation: Possible trigger of Parkinson's disease.
    Kasen A; Houck C; Burmeister AR; Sha Q; Brundin L; Brundin P
    Neurobiol Dis; 2022 May; 166():105654. PubMed ID: 35143968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New therapeutic approaches to target alpha-synuclein in Parkinson's disease: The role of immunotherapy.
    Fernández-Valle T; Gabilondo I; Gómez-Esteban JC
    Int Rev Neurobiol; 2019; 146():281-295. PubMed ID: 31349931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha-synuclein Immunization Strategies for Synucleinopathies in Clinical Studies: A Biological Perspective.
    Knecht L; Folke J; Dodel R; Ross JA; Albus A
    Neurotherapeutics; 2022 Sep; 19(5):1489-1502. PubMed ID: 36083395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effects of immunotherapy with antibodies targeting α-synuclein oligomers and fibrils in a transgenic model of synucleinopathy.
    El-Agnaf O; Overk C; Rockenstein E; Mante M; Florio J; Adame A; Vaikath N; Majbour N; Lee SJ; Kim C; Masliah E; Rissman RA
    Neurobiol Dis; 2017 Aug; 104():85-96. PubMed ID: 28476636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiological and pathological properties of alpha-synuclein.
    Tofaris GK; Spillantini MG
    Cell Mol Life Sci; 2007 Sep; 64(17):2194-201. PubMed ID: 17605001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Living in Promiscuity: The Multiple Partners of Alpha-Synuclein at the Synapse in Physiology and Pathology.
    Longhena F; Faustini G; Spillantini MG; Bellucci A
    Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30609739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphic Alpha-Synuclein Oligomers: Characterization and Differential Detection with Novel Corresponding Antibodies.
    Moore K; Sengupta U; Puangmalai N; Bhatt N; Kayed R
    Mol Neurobiol; 2023 May; 60(5):2691-2705. PubMed ID: 36707462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How specific are the conformation-specific α-synuclein antibodies? Characterization and validation of 16 α-synuclein conformation-specific antibodies using well-characterized preparations of α-synuclein monomers, fibrils and oligomers with distinct structures and morphology.
    Kumar ST; Jagannath S; Francois C; Vanderstichele H; Stoops E; Lashuel HA
    Neurobiol Dis; 2020 Dec; 146():105086. PubMed ID: 32971232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. α-Synuclein oligomers induce early axonal dysfunction in human iPSC-based models of synucleinopathies.
    Prots I; Grosch J; Brazdis RM; Simmnacher K; Veber V; Havlicek S; Hannappel C; Krach F; Krumbiegel M; Schütz O; Reis A; Wrasidlo W; Galasko DR; Groemer TW; Masliah E; Schlötzer-Schrehardt U; Xiang W; Winkler J; Winner B
    Proc Natl Acad Sci U S A; 2018 Jul; 115(30):7813-7818. PubMed ID: 29991596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alteration of Structure and Aggregation of α-Synuclein by Familial Parkinson's Disease Associated Mutations.
    Sahay S; Ghosh D; Singh PK; Maji SK
    Curr Protein Pept Sci; 2017; 18(7):656-676. PubMed ID: 26972727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Hidden Cell-to-Cell Trail of α-Synuclein Aggregates.
    Neupane S; De Cecco E; Aguzzi A
    J Mol Biol; 2023 Jun; 435(12):167930. PubMed ID: 36566800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review: Spreading the word: precise animal models and validated methods are vital when evaluating prion-like behaviour of alpha-synuclein.
    Rey NL; George S; Brundin P
    Neuropathol Appl Neurobiol; 2016 Feb; 42(1):51-76. PubMed ID: 26666838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibrillar form of α-synuclein-specific scFv antibody inhibits α-synuclein seeds induced aggregation and toxicity.
    Gupta V; Salim S; Hmila I; Vaikath NN; Sudhakaran IP; Ghanem SS; Majbour NK; Abdulla SA; Emara MM; Abdesselem HB; Lukacsovich T; Erskine D; El-Agnaf OMA
    Sci Rep; 2020 May; 10(1):8137. PubMed ID: 32424162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.